The proposed ADM Scientist Development Award (K21) outlines a five-year program of training and research in substance abuse with a focus on treatment development for HIV-positive intravenous drug abusers. The candidate is a health psychologist and junior faculty member at Yale University, whose primary preceptor is Bruce Rounsaville, M.D., an established researcher with an outstanding record of mentoring research scientists. Other preceptors include Kathleen Carroll, Ph.D., Edward Kaplan, Ph.D., Thomas Kosten, M.D., Richard Schottenfeld, M.D., and Peter Selwyn, M.D., all established investigators in the field of substance abuse and AIDS. The research plan has three parts: (a) an assessment study examining methadone patients' high-risk attitudes and behaviors from a Health Belief Model perspective; (b) a retrospective matching study in which the differential efficacy of standard Coping Skills Training, alone or in combination with pharmacologic and non- pharmacologic treatments, will be investigated for reducing high risk behaviors in methadone patients, using HIV status as a matching variable; and (c) a Stage I behavioral therapies project, in response to PA-94-078, in which Risk Reduction Therapy (RRT) will be developed and evaluated. RRT is a modified coping skills training approach to HIV risk reduction adapted to meet the special needs of HIV-positive drug abusers through inclusion of cognitive remediation strategies and attention to the medical and emotional needs of this patient population. The career development plan includes formal course work and mentoring in psychotherapy development and process research, biostatistics, chronic disease and HIV/AIDS epidemiology, and neuropharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Scientist Development Award (K21)
Project #
5K21DA000277-04
Application #
2770040
Study Section
Special Emphasis Panel (SRCD (12))
Project Start
1995-09-01
Project End
2000-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
St Helen, Gideon; Goniewicz, Maciej L; Dempsey, Delia et al. (2012) Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem Res Toxicol 25:952-64
Avants, S Kelly; Margolin, Arthur; Usubiaga, Mary Helen et al. (2004) Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat 26:67-78
Margolin, Arthur; Avants, S Kelly; Warburton, Lara A et al. (2003) A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol 22:223-8
Copenhaver, Michael; Avants, S Kelly; Warburton, Lara A et al. (2003) Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J Psychoactive Drugs 35:209-18
Arnold, RuthM; Avants, S Kelly; Margolin, Arthur et al. (2002) Patient attitudes concerning the inclusion of spirituality into addiction treatment. J Subst Abuse Treat 23:319-26
Margolin, Arthur; Avants, S Kelly; Warburton, Lara A et al. (2002) Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care STDS 16:255-67
Avants, S K; Warburton, L A; Margolin, A (2001) Spiritual and religious support in recovery from addiction among HIV-positive injection drug users. J Psychoactive Drugs 33:39-45
Avants, S K; Margolin, A; Warburton, L A et al. (2001) Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict 10:69-78
Avants, S K; Warburton, L A; Margolin, A (2001) How injection drug users coped with testing HIV-seropositive: implications for subsequent health-related behaviors. AIDS Educ Prev 13:207-18
Avants, S K; Warburton, L A; Hawkins, K A et al. (2000) Continuation of high-risk behavior by HIV-positive drug users. Treatment implications. J Subst Abuse Treat 19:15-22